These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 14705825

  • 1. Combined treatment with ursodeoxycholic acid and pioglitazone in a patient with NASH associated with type 2 diabetes and psoriasis.
    Itoh S, Kanazuka A, Akimoto T.
    Dig Dis Sci; 2003 Nov; 48(11):2182-6. PubMed ID: 14705825
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Type 2 diabetes, psoriasis and thiazolidinediones.
    Krentz AJ, Friedmann PS.
    Int J Clin Pract; 2006 Mar; 60(3):362-3. PubMed ID: 16494655
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Treatment of NASH with ursodeoxycholic acid: pros and cons. More information in children.
    Vajro P, Paolella G, Pierri L, D'Aniello R.
    Clin Res Hepatol Gastroenterol; 2013 Jun; 37(3):e93-4. PubMed ID: 23562789
    [No Abstract] [Full Text] [Related]

  • 7. Therapy for nonalcoholic fatty liver disease.
    Moseley RH.
    J Clin Gastroenterol; 2008 Apr; 42(4):332-5. PubMed ID: 18277910
    [No Abstract] [Full Text] [Related]

  • 8. Thiazolidinediones for nonalcoholic steatohepatitis--promising but not ready for prime time.
    McCullough AJ.
    N Engl J Med; 2006 Nov 30; 355(22):2361-3. PubMed ID: 17135591
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pharmacologic therapy of non-alcoholic steatohepatitis.
    Ratziu V, Zelber-Sagi S.
    Clin Liver Dis; 2009 Nov 30; 13(4):667-88. PubMed ID: 19818312
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. UDCA for NASH: end of the story?
    Haedrich M, Dufour JF.
    J Hepatol; 2011 May 30; 54(5):856-8. PubMed ID: 21145815
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Fatty liver and raised gamma-GT: it can happen to abstainers, too].
    Bischoff A.
    MMW Fortschr Med; 2002 Feb 14; 144(7):18. PubMed ID: 11887726
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study.
    Georgescu EF, Georgescu M.
    J Gastrointestin Liver Dis; 2007 Mar 14; 16(1):39-46. PubMed ID: 17410287
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.